Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels
作者： Carlo Gambacorti-Passerini , Rocco Piazza , Maurizio D'Incalci , None
DOI: 10.1182/BLOOD-2003-05-1629
关键词:
摘要: Corbin and colleagues analyze in their report[1][1] the biochemical biologic effects of several mutations kinase domain Bcr-Abl protein identified patients who developed resistance to imatinib. Some (6 9 studied here) confer only a modest index (less than
ashpublications.org
elsevier.com
sci-hub.se 参考文章(13)
Michael W.N. Deininger, John M. Goldman, Nicholas Lydon, Junia V. Melo, The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells Blood. ,vol. 90, pp. 3691- 3698 ,(1997) , 10.1182/BLOOD.V90.9.3691
Christophe Barthe, Pascale Cony-Makhoul, Junia V Melo, Josy Reiffers François-Xavier Mahon, None, Roots of Clinical Resistance to STI-571 Cancer Therapy Science. ,vol. 293, pp. 2163a- 2163 ,(2001) , 10.1126/SCIENCE.293.5538.2163A
Susan M. Graham, Heather G. Jørgensen, Elaine Allan, Charlie Pearson, Michael J. Alcorn, Linda Richmond, Tessa L. Holyoake, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood. ,vol. 99, pp. 319- 325 ,(2002) , 10.1182/BLOOD.V99.1.319
Jérôme Larghero, Thibaut Leguay, Samia Mourah, Isabelle Madelaine-Chambrin, Anne-Laure Taksin, Emmanuel Raffoux, Jean-Noel Bastie, Laurent Degos, Patrice Berthaud, Jean-Pierre Marolleau, Fabien Calvo, Christine Chomienne, François-Xavier Mahon, Philippe Rousselot, Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochemical Pharmacology. ,vol. 66, pp. 1907- 1913 ,(2003) , 10.1016/S0006-2952(03)00469-6
Mercedes E Gorre, Mansoor Mohammed, Katharine Ellwood, Nicholas Hsu, Ron Paquette, P Nagesh Rao, Charles L Sawyers, Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification Science. ,vol. 293, pp. 876- 880 ,(2001) , 10.1126/SCIENCE.1062538
Catherine Roche-Lestienne, Valerie Soenen-Cornu, Nathalie Grardel-Duflos, Jean-Luc Laı̈, Nathalie Philippe, Thierry Facon, Pierre Fenaux, Claude Preudhomme, Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood. ,vol. 100, pp. 1014- 1018 ,(2002) , 10.1182/BLOOD.V100.3.1014
Amie S. Corbin, Paul La Rosée, Eric P. Stoffregen, Brian J. Druker, Michael W. Deininger, Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. ,vol. 101, pp. 4611- 4614 ,(2003) , 10.1182/BLOOD-2002-12-3659
Heather G. Jørgensen, Moira A. Elliott, Elaine K. Allan, Christine E. Carr, Tessa L. Holyoake, Kevin D. Smith, Alpha1-acid Glycoprotein Expressed in the Plasma of Chronic Myeloid Leukemia Patients Does Not Mediate Significant in Vitro Resistance to STI571 Blood. ,vol. 99, pp. 713- 715 ,(2002) , 10.1182/BLOOD.V99.2.713
C. Gambacorti-Passerini, Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571 Journal of the National Cancer Institute. ,vol. 92, pp. 1641- 1650 ,(2000) , 10.1093/JNCI/92.20.1641
Carlo B. Gambacorti-Passerini, Francesca Rossi, Magda Verga, Holger Ruchatz, Rosalind Gunby, Roberta Frapolli, Massimo Zucchetti, Leonardo Scapozza, Silvia Bungaro, Lucia Tornaghi, Fabio Rossi, Pietro Pioltelli, Enrico Pogliani, Maurizio D'Incalci, Gianmarco Corneo, Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Molecules and Diseases. ,vol. 28, pp. 361- 372 ,(2002) , 10.1006/BCMD.2002.0526